CHRO Chromocell: Price-to-Projected Revenue Ratio
Component supply stability and international certification are critical to the operations of Chromocell Therapeutics (CHRO). The forward P/S indicator reflects the business valuation relative to expected sales, with the metric currently at . Unique pain-fighting molecules create potential for premium pricing power. Finally, the absence of large-scale manufacturing facilities reduces environmental risks to standard chemical disposal regulations.
Analytical breakdowns for Chromocell (CHRO)
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- business debt structure and liquidity details:
Total Debt to Equity Ratio Chromocell Therapeutics|CHRO - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Chromocell Therapeutics|CHRO - Aggregate Debt Obligations|Debts to Book Capitalization Chromocell|CHRO - Long-Term Debt|Company Short-Term Debt Chromocell Therapeutics|Quick Ratio chromocell.com
- business earnings and investment ratios data:
CHRO - Net Profit|Expected Profit Chromocell Therapeutics|CHRO - Market Cap to Net Income|Forward P/E Multiple Chromocell Therapeutics Corporation|CHRO - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Chromocell|CHRO - Operating profit EBITDA|Net earnings per share for the last 12 months Chromocell Therapeutics|CHRO - Earnings per share for the last four quarters|Quarterly EPS earnings growth chromocell.com|CHRO - Expected net earnings per share growth this year|Earnings growth forecast for next year Chromocell Therapeutics
- sales revenue and business income indicators:
Summary company analysis:Chromocell Therapeutics Corp. CHRO
Forward P/S determines the market value of a business relative to expected annual revenue, allowing for an assessment of the premium paid for potential sales growth. By analyzing the projected P/S of the business, an investor can see the speculative nature of the valuation of Chromocell Therapeutics (CHRO), as the lack of commercial products and reliance on external financing make this multiple an indicator of market confidence in the success of early clinical trials.
Competitor analysis
Forward P/S Multiple BIIB (Biogen)|Neurocrine (NBIX) - Market Cap to Future Revenue Ratio|RGC - Price-to-Projected Revenue Ratio|AXSM: Price-to-Projected Revenue Ratio|ACADIA Pharmaceuticals (ACAD) - Price-to-Projected Revenue Ratio|XENE (xenon-pharma.com) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple VKTX|SUPN: Forward Price to Sales|Forward Price-to-Revenue Multiple CPRX (Catalyst Pharmaceuticals Inc)|Price to Expected Revenue Ratio DNLI|Forward P/S Multiple HRMY (Harmony Biosciences)|Forward Price to Sales BHVN|Amylyx Pharmaceuticals, Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Trevi Therapeutics Inc|Praxis Medicines (PRAX) - Price-to-Projected Revenue Ratio|Anavex Life Sciences Corp - Forward Price to Sales|CBLL (CeriBell, Inc.) - Forward P/S Multiple|Forward P/S Multiple Prothena Corporation|Price-to-Projected Revenue Ratio Alector, Inc. (ALEC)|ANNX: Future Price to Revenue|Forward P/S Multiple OMER (Omeros)|Neurogene Therapeutics (NGNE) - Market Cap to Future Revenue Ratio|ACIU: Forward Price-to-Revenue Multiple|VYGR - Forward P/S Multiple|NMRA (Neumora Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|SCLX: Price to Expected Revenue Ratio|TVGN (Tevogen Bio Holdings, Inc.) - Forward P/S Multiple|Alpha Cognition Corp (ACOG) - Market Cap to Expected Sales Ratio|Forward P/S Multiple CGTX|Forward Price-to-Revenue Multiple inhibikase.com IKT|Price-to-Projected Revenue Ratio Cassava Sciences SAVA|Market Cap to Expected Sales Ratio Assertio Holdings (ASRT)|Coya - Forward P/S Multiple|Vistagen Therapeutics (VTGN) - Forward Price-to-Revenue Multiple|OVID: Forward P/S Multiple|acumenpharm.com - Forward Price to Sales|Price-to-Projected Revenue Ratio CervoMed|ATHE: Forward Price to Sales|Price-to-Projected Revenue Ratio Clene Inc. (CLNN)|PEPG - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Jupiter Neurosciences Inc JUNS|RLMD: Market Cap to Projected Revenue|Annovis Bio - Forward P/S Multiple|Market Cap to Future Revenue Ratio Grace Therapeutics, Inc.|AIFF (Firefly Neuroscience Inc) - Forward Price-to-Revenue Multiple|Klotho Neurosciences (KLTO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio NeuroSense Therapeutics Ltd|RVPH: Forward Price to Sales|Price-to-Projected Revenue Ratio MetaVia Inc (MTVA)|NRXS - Market Cap to Future Revenue Ratio|Forward P/S Multiple HSDT (Helius Medical Technologies)|PASG - Forward Price-to-Revenue Multiple|Neuphoria - Forward P/S Multiple|Forward Price to Sales NERV (minervaneurosciences.com)|Athira Pharma (ATHA) - Price-to-Projected Revenue Ratio|Addex Therapeutics Ltd. - Forward Price to Sales|Price-to-Projected Revenue Ratio Alzamend Neuro Inc.|Market Cap to Future Revenue Ratio Cyclerion CYCN|Price-to-Projected Revenue Ratio Protagenic Therapeutics (PTIX)|Forward Price-to-Revenue Multiple pasitheaclinics.com KTTA|Price-to-Projected Revenue Ratio Cortigent CRGT|Avenue Therapeutics Inc. (ATXI) - Market Cap to Future Revenue Ratio|Brainstorm Cell Therapeutics, Inc. - Forward P/S Multiple|Cara Therapeutics Inc (CARA) - Forward Price-to-Revenue Multiple|ELYM: Forward P/S Multiple|Market Cap to Future Revenue Ratio Intra-Cellular Therapies, Inc. (ITCI)|Price-to-Projected Revenue Ratio Longboard Pharmaceuticals, Inc.|Price-to-Projected Revenue Ratio MRNS|Price-to-Projected Revenue Ratio NKGen (NKGN)|Price-to-Projected Revenue Ratio NRBO (NeuroBo Pharma)|Sage Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales SNPX|TRVN: Forward Price-to-Revenue Multiple|Vigil Neuroscience - Price to Expected Revenue Ratio|WENA: Forward P/S Multiple|Cerevel Corp - Forward Price to Sales
